© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 31, 2021
During a Targeted Oncology Case-Based Peer Perspectives Roundtable, Tanya Dorff, MD, reviews the available treatment options for nonmetastatic castration-resistant prostate cancer to select a treatment for 57-year-old patient.
February 19, 2019
Tanya Dorff, MD, discusses recent data with olaparib (Lynparza) in castration-resistant prostate cancer and the future role of PARP inhibitors in this disease.